Molecular diagnostics, next-generation sequencing (NGS), and genetic testing billing require accurate coding, payer-specific coverage verification, medical necessity documentation, and consistent denial management. In 2027, laboratories need a proactive revenue cycle strategy to address reimbursement challenges, reduce avoidable claim denials, and maintain financial stability.
In this guide, we explain the key aspects of molecular diagnostics and genetic testing billing, including eligibility verification, prior authorization, coding requirements, medical necessity, denial prevention, A/R management, and Medicare Clinical Laboratory Fee Schedule (CLFS) updates for 2027. We also explore how laboratories can monitor reimbursement performance and strengthen revenue cycle management (RCM) to support more efficient billing operations.
Why Is Molecular Diagnostics Billing So Complex?
Molecular diagnostics billing is complex because reimbursement depends on the relationship between the test performed, the clinical indication, the patient’s coverage, the applicable coding requirements, and the payer’s reimbursement rules.
Two tests that appear clinically similar may have different coverage criteria or claim requirements. Requirements can also vary among Medicare, Medicare Administrative Contractors (MACs), Medicaid programs, and commercial health plans.
Common sources of billing difficulty include:
- Incorrect or incomplete patient and insurance information
- Unverified benefits or unclear coverage for the ordered test
- Missing prior authorization when required
- Documentation that does not sufficiently support medical necessity
- Incorrect CPT or HCPCS code selection, units, or claim details
- Test-specific identifier requirements that are not satisfied
- Incomplete or inconsistent information transferred from laboratory systems
- Untimely claim submission or follow-up
- Denials that are not categorized and addressed at their root cause
The solution is not to rely on claim submission speed alone. Laboratories need a revenue cycle process that identifies reimbursement risks early, applies the relevant payer rules, and tracks each claim through final resolution.
The Molecular Diagnostics Billing Workflow: From Order to Payment
The most effective way to evaluate a molecular or genetic testing revenue cycle is to examine each stage separately.
| Revenue cycle stage | What to review | Common financial risk |
|---|---|---|
| Order intake | Patient information, ordering provider, requested test, and clinical indication | Incomplete or inconsistent claim information |
| Eligibility and coverage | Active coverage, benefits, network or laboratory requirements, and applicable test coverage | Testing proceeds without a clear understanding of the payment pathway |
| Prior authorization | Whether the specific plan and test require authorization, notification, or other approval steps | Authorization-related denials and administrative delays |
| Documentation | Order, diagnosis, medical necessity support, and required records | Medical-necessity denials or requests for additional information |
| Coding and claim preparation | Applicable CPT/HCPCS code, units, identifiers, and claim-specific instructions | Coding errors, rejected claims, or missing required information |
| Claim submission | Claim edits, payer routing, required attachments, and timely filing | Front-end rejections or avoidable processing delays |
| Payment and denial management | Remittance review, payment variance, corrections, appeals, and A/R follow-up | Underpayments, repeated denials, and aging receivables |
This workflow should be adapted to the laboratory’s actual test menu, contracts, payer mix, and technology environment. Not every test follows the same reimbursement pathway, and not every payer requires the same information.
1. Verify Eligibility, Benefits and Coverage Before Testing
Eligibility verification is an important first step, but active insurance coverage does not guarantee that a particular genetic or molecular test will be covered.
A laboratory should distinguish among three separate questions:
- Is the patient’s coverage active for the relevant date of service?
- What benefits, network restrictions, authorization requirements, and patient financial responsibilities apply?
- Does the payer’s applicable policy cover the specific test for the documented clinical indication?
These questions are related, but they are not interchangeable.
A verification workflow should capture the payer’s response, the information checked, the date of verification, and any follow-up that remains necessary. Where applicable, staff should confirm whether the testing laboratory meets the plan’s requirements.
For high-cost or complex tests, unresolved coverage questions should be escalated to the appropriate team before testing whenever operationally and clinically appropriate.
Practical recommendation: Create a test-and-payer reference process that helps staff identify recurring coverage questions without assuming that a previous decision guarantees the outcome for another patient.
2. Make Prior Authorization Part of the Front-End Workflow
Prior authorization can create significant administrative and financial challenges when its requirements are discovered late.
However, there is no universal rule that every molecular or genetic test requires prior authorization. Requirements depend on the payer, plan, test, clinical indication, and applicable policy. Some situations may involve notification or other administrative requirements instead of authorization.
Laboratories should establish a process to identify applicable requirements as early as practical.
A useful authorization workflow includes:
- Identifying the test and payer before initiating the authorization check
- Confirming what information the payer requires
- Coordinating with the ordering provider when clinical records or clarification are needed
- Tracking authorization status, reference numbers, dates, and applicable validity periods
- Confirming that the authorization corresponds to the test and circumstances being billed
- Documenting the final outcome and communicating unresolved issues to the appropriate team
Authorization should not be treated as a guarantee of payment. The claim may still be subject to other coverage conditions, medical necessity requirements, coding rules, and claim edits.
The operational objective is to prevent avoidable problems while keeping billing requirements appropriately coordinated with clinical care.
3. Support Medical Necessity With Complete Documentation
Medical necessity is a central consideration in genetic testing billing, molecular pathology billing, and NGS reimbursement. Documentation should support the service billed and the applicable payer’s coverage criteria. Depending on the test and policy, relevant information may include:
- The test order and ordering provider information
- The patient’s diagnosis, signs, symptoms, or other documented clinical indication
- Relevant clinical history and supporting records
- Documentation required by the specific coverage policy
- The test performed and the associated laboratory report, where applicable
- Information supporting applicable frequency, sequencing, or other coverage limitations
Not every claim requires every item listed above. The required documentation should be determined by the applicable payer policy, coverage determination, and service being billed.
A diagnosis code alone may not adequately establish medical necessity when a payer requires additional clinical information.
Laboratories should also establish a process for responding to payer requests for medical records and additional documentation within the relevant deadlines.
For Medicare, laboratories should consult applicable national coverage determinations, local coverage determinations, and associated billing and coding articles. The CMS Medicare Coverage Database provides access to these coverage resources.
4. Get Molecular Pathology and NGS Coding Right
Accurate coding requires more than identifying a broad category of laboratory testing. The code submitted must appropriately represent the service performed and follow the requirements applicable to that test and payer.
Depending on the service, coding may involve molecular pathology CPT codes, other appropriate CPT or HCPCS codes, or a proprietary laboratory analysis (PLA) code when applicable.
Laboratories should review the following before submitting claims:
- Does the code accurately describe the test or service performed?
- Is the code appropriate for the assay, methodology, and service being billed?
- Are units of service accurate and consistent with applicable instructions?
- Does the claim contain the required diagnosis and supporting information?
- Are applicable payer-specific identifiers, modifiers, or additional claim details included?
- Are current code descriptions, effective dates, and payer policies being used?
- Does the claim comply with the applicable billing and coding guidance?
For applicable laboratory claims, accurate place-of-service reporting is also essential. Review our guide to POS 81 billing requirements to understand when this code applies.
What Is the MolDX Z-Code Requirement?
The Medicare Molecular Diagnostic Services (MolDX) program includes test identification and coverage requirements for applicable molecular diagnostic tests.
Under applicable MolDX billing guidance, claims for covered molecular diagnostic tests may need a DEX Z-Code identifier associated with the appropriate CPT code and submitted in the required claim field. The precise instructions depend on the applicable policy and claim type.
This is not a universal requirement for every molecular test or every payer . Laboratories should determine whether MolDX applies to the test and claim, then follow the relevant local coverage determination and billing and coding article.
Consult the official CMS MolDX: Molecular Diagnostic Tests coverage policy and its associated billing and coding guidance for applicable requirements.
Another important distinction is that a code appearing on the Medicare Clinical Laboratory Fee Schedule does not itself establish coverage. CMS explicitly notes that listing a code or payment amount on the CLFS does not imply that Medicare will cover the test.
5. Make Denial Management a Prevention Strategy
A denied molecular testing claim often triggers additional work: reviewing the remittance, researching the payer’s explanation, retrieving documentation, correcting the claim, resubmitting it, or preparing an appeal.
Even when payment is eventually received, repeated claim rework consumes staff time and can delay cash flow.
A stronger denial management process separates the immediate resolution of a claim from the longer-term prevention of similar problems.
Common denial categories to monitor include:
- Eligibility and coordination-of-benefits issues
- Missing or incomplete authorization
- Medical necessity and coverage limitations
- Incorrect or unsupported coding
- Missing records or required claim information
- Test-specific identifier requirements
- Duplicate claims, claim processing errors, or timely filing concerns
The appropriate response depends on the actual denial reason. A claim should not automatically be appealed or resubmitted without determining whether a correction, additional information, a formal appeal, or another action is appropriate.
Build a Repeatable Denial Review Process
- First, classify the denial. Record the payer, test or code, denial reason, date, and amount at risk.
- Second, investigate the root cause. Determine whether the issue originated during order intake, eligibility verification, authorization, documentation, coding, claim preparation, or payer processing.
- Third, take the appropriate corrective action. Correct errors, obtain supporting information, submit a reconsideration or appeal when warranted, and observe applicable filing deadlines.
- Fourth, address the underlying workflow. If the same problem recurs, revise the relevant checklist, system edit, handoff, or staff procedure.
- Finally, measure recurrence. Determine whether the corrective action reduces the frequency of similar denials over subsequent reporting periods.
- This approach helps laboratories use denial data as operational intelligence rather than treating every denied claim as an isolated event.
For revenue cycle support, HealthQuest Billing provides denial and appeal management among its published medical billing services.
6. Connect Laboratory Operations With Billing Workflows
Laboratory information systems (LIS), laboratory information management systems (LIMS), and billing platforms may support different parts of the same revenue cycle.
When information does not transfer consistently, staff may need to re-enter data, reconcile records, investigate mismatches, or manually track missing claim details.
These manual steps can increase administrative workload and introduce avoidable errors.
Laboratories should evaluate whether their systems and processes transfer the information needed for billing, including patient and payer details, test identifiers, order information, service dates, and relevant result or documentation status.
Before implementing an integration or outsourcing arrangement, establish clear responsibilities for:
- Data transfer and reconciliation
- Required fields and validation checks
- Missing or inconsistent information
- Work queues and exception handling
- Claim submission and status updates
- Access controls and data protection
- Issue escalation and reporting
Not every billing service includes LIS/LIMS integration, and compatibility should not be assumed. Laboratories should confirm their prospective partner’s technical capabilities and scope of work before relying on automated information exchange.
The goal is a dependable process in which required information reaches the billing workflow accurately, exceptions are visible, and manual intervention is reduced where practical.
7. PAMA and the 2027 Medicare Clinical Laboratory Fee Schedule
The 2027 Medicare Clinical Laboratory Fee Schedule is a significant issue for laboratories evaluating reimbursement, test-level profitability, and future cash flow. The Protecting Access to Medicare Act of 2014 (PAMA) established a market-based approach to Medicare payment for many clinical diagnostic laboratory tests, using weighted median private payer rates as a basis for setting CLFS payment rates.
What Changed in the 2026 Reporting Cycle?
CMS states that the 2026 PAMA reporting period ran from May 1 through July 31, 2026, using applicable data collected from January 1 through June 30, 2025.
That reporting cycle informed the preliminary CY 2027 CLFS rates.
On September 21, 2026, CMS published preliminary weighted median private payer rates for certain clinical diagnostic laboratory tests. The agency indicated that the final CY 2027 rates were expected in November 2026, before taking effect on January 1, 2027.
According to CMS’s preliminary 2027 CLFS fact sheet , the preliminary comparisons showed:
| Test category | Codes with preliminary weighted median data | Potential average change compared with CY 2026 CLFS |
|---|---|---|
| Molecular pathology | 211 | -22% |
| Genomic sequencing | 42 | -23% |
These figures are preliminary category-level comparisons, not guaranteed changes to individual test payments. Final rates, code-specific payment limits, applicable statutory reductions, and coverage requirements must be assessed separately.
What Does the 15% Annual Reduction Limit Mean?
The Consolidated Appropriations Act, 2026, changed the phase-in of CLFS payment reductions. CMS states that beginning in 2027 and continuing through 2029, payment for a test may not be reduced by more than 15% per year compared with the amount established for that test in the preceding year.
The 15% figure is an annual reduction limit. It does not mean that every laboratory test will receive a 15% cut.
For a laboratory, the practical questions are more specific:
- Which codes represent the largest share of Medicare revenue?
- Which tests may be most exposed to payment changes?
- What proportion of volume is Medicare versus commercial or Medicaid?
- How do current reimbursement levels compare with expected payment under the applicable fee schedule?
- How much do denials, underpayments, and administrative costs affect net revenue by test?
- What would different reimbursement scenarios mean for cash flow and operational planning?
Laboratories should use the final CY 2027 CLFS rates and applicable coverage policies to update their analyses once published. The CMS Clinical Laboratory Fee Schedule resource is the appropriate starting point for official rates and updates.
Does a CLFS Payment Rate Guarantee Medicare Coverage?
No. A fee schedule rate and coverage eligibility are separate questions.
A laboratory should verify that the test meets the applicable Medicare coverage requirements and that the claim satisfies relevant coding, documentation, and billing instructions. The presence of a payment amount on the CLFS alone does not guarantee payment for a particular claim.
The same discipline applies to commercial and Medicaid claims: use the applicable plan documents, contracts, coverage rules, and reimbursement policies rather than assuming that one payer’s decision establishes another payer’s requirements.
8. Which Revenue Cycle Metrics Should Molecular Laboratories Track?
A useful laboratory RCM dashboard should show where revenue is being earned, delayed, denied, underpaid, or consumed by administrative work.
Total monthly collections are important, but they do not explain why performance is improving or deteriorating.
Laboratory executives should consider tracking:
| Metric | Why it matters |
|---|---|
| Clean claim rate | Shows how often claims pass initial edits without avoidable correction or rework; define the measurement consistently |
| Initial denial rate | Identifies the proportion of claims denied at first adjudication |
| Denials by payer and test code | Highlights concentrated reimbursement and workflow problems |
| Authorization-related denials | Helps identify gaps in authorization checks or documentation |
| Medical necessity denials | Indicates a need to review coverage criteria, orders, diagnosis information, and supporting records |
| A/R aging | Shows how much outstanding revenue sits in different age bands, including receivables over 90 days |
| Days in A/R | Provides a view of the time receivables remain outstanding when calculated consistently |
| Payment variance by test | Helps identify differences between expected and actual reimbursement |
| Net collection by payer and test | Helps leadership assess actual reimbursement after relevant adjustments and write-offs |
| Appeal overturn rate | Helps assess appeal outcomes when tracked with consistent definitions |
| Manual touches per claim | Indicates where automation, clearer handoffs, or process redesign might reduce work |
Metrics should be segmented by payer, test category, claim type, and other operationally meaningful factors. A rising denial rate for one test or payer may disappear inside an overall average.
Definitions must remain consistent across reporting periods. For example, a claim acceptance rate is not necessarily the same as a first-pass payment rate, and a denial overturn rate should specify which resolved claims are included in its denominator.
The purpose of reporting is not simply to produce a dashboard. It is to identify the actions that can improve reimbursement operations.
9. Should a Molecular Laboratory Outsource Billing or Keep It In-House?
There is no single answer for every laboratory.
An experienced internal billing team may be well suited to managing the revenue cycle, particularly when it has the necessary coding expertise, payer knowledge, reporting capabilities, and resources to maintain current workflows.
Other laboratories may face staffing shortages, growing claim volumes, inconsistent denial follow-up, or difficulties managing reimbursement rules across multiple payers. They may benefit from outside billing and RCM support.
A third option is a hybrid model in which internal staff retain operational responsibilities while an external partner supports selected functions, such as coding review, denial management, A/R follow-up, audits, or reporting.
The right approach depends on the laboratory’s test menu, claim volume, payer mix, internal expertise, current performance, technology, and financial objectives.
Key Takeaways for Molecular and Genetic Testing Billing in 2027
- Verify coverage before testing when practical. Eligibility, benefits, prior authorization, and test-specific coverage requirements should be reviewed early enough to address potential problems.
- Support medical necessity. The order, diagnosis, clinical documentation, and test performed should support the applicable payer’s coverage criteria.
- Use accurate, test-specific coding. CPT or HCPCS coding, units, identifiers, and supporting claim information must follow the applicable billing requirements.
- Treat the 2027 Medicare CLFS update as a financial planning priority. Preliminary CMS comparisons indicate potential downward reimbursement pressure in molecular pathology and genomic sequencing, but final rates and individual test impacts must be evaluated separately.
- Turn denial data into prevention. Recurring eligibility, authorization, documentation, coding, and coverage issues should trigger workflow improvements rather than repeated claim rework.
- Measure reimbursement by test and payer. Overall collections alone may not reveal which parts of the laboratory’s test menu are creating avoidable costs or financial risk.
Questions to Ask Before Selecting an RCM Partner
Before entering an agreement, a laboratory should ask a prospective billing company:
- What experience does your team have with our specific laboratory tests and payer mix?
- Who verifies coverage, authorization requirements, and medical necessity documentation?
- How are molecular pathology and NGS coding requirements reviewed and updated?
- How are denied claims categorized, appealed, and analyzed for recurring causes?
- What reports will we receive, and how frequently?
- What technology integrations are supported, and what falls outside the contract?
- How will responsibilities, turnaround times, escalation, data protection, and performance measures be defined?
These questions help the laboratory evaluate whether a proposed service model is appropriate instead of assuming that every medical billing provider offers the same laboratory-specific capabilities.
Build a Revenue Cycle That Keeps Pace With Molecular Diagnostics
Molecular diagnostics, next-generation sequencing, and genetic testing will continue to advance. The financial processes supporting those tests must remain equally disciplined. For laboratories, a resilient revenue cycle starts with accurate order and patient information, applies the relevant coverage and coding requirements, reduces avoidable rework, tracks payer-specific performance, and follows claims through payment or appropriate resolution.
The 2027 Medicare CLFS changes make test-level reimbursement analysis particularly important. At the same time, consistent eligibility checks, documentation, denial prevention, and A/R management remain essential to understanding how much revenue the laboratory earns and how efficiently it collects it.
HealthQuest Billing provides medical billing and revenue cycle services that include coding, denial and appeal management, accounts receivable, payment posting, auditing, reporting, and RCM optimization. The next step for a laboratory is to evaluate its specific test menu, payer mix, workflow needs, and required level of specialized support.
Ready to review your billing workflow? Contact HealthQuest Billing to discuss your organization’s revenue cycle needs.
